Skip to content
Home/Companies/MedTech/Regenity Biosciences
Regenity Biosciences

Regenity Biosciences

MedTech·US·Active·New
Entry
2026
Hold
New
Status
Active

Who owns Regenity Biosciences?

Regenity Biosciences is currently owned by Cinven through Cinven Fund VIII (2024 vintage), since 2026.

Hand-verified · updated 2026-04-21

Cinven
Investor
Cinven
Cinven Fund VIII · 2024 · Buyout

Key facts

HQUnited States
SectorMedTech
Websiteregenity.com

More from Cinven Fund VIII

Other portfolio companies in the same fund.

Salsify
Active
SaaSUS· 2026
Artefact
Artefact
Active
Business ServicesUK· 2025
Flint Global
Flint Global
Active
Business ServicesUK· 2025
Grant Thornton
Grant Thornton
Active
FinancialsUK· 2025
Nutrisens
Nutrisens
Active
HealthcareFrance· 2025
Objectway
Active
FintechUK· 2025

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Track Regenity Biosciences

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Regenity Biosciences?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Regenity Biosciences.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue